NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

VERV

Verve Therapeutics Inc

May 16 • 04:00PM ET

4.63

Dollar change +0.31
Percentage change 7.18	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BEAM EDIT CRBU DTIL SGMO CLLS QURE BLRX

| Held by: VTI IWM XBI VXF IWN VTWO IBB SCHA VHT AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	27.10%	Shs Outstand	88.80M	Perf Week	9.46%
Market Cap	412.73M	Forward P/E	-	EPS next Y	-2.69	Insider Trans	-0.10%	Shs Float	64.98M	Perf Month	2.66%
Income	-181.01M	PEG	-	EPS next Q	-0.67	Inst Own	73.78%	Short Float	28.49%	Perf Quarter	-46.04%
Sales	59.61M	P/S	6.92	EPS this Y	-1.90%	Inst Trans	8.46%	Short Ratio	6.16	Perf Half Y	-27.77%
Book/sh	5.33	P/B	0.87	EPS next Y	-12.34%	ROA	-26.89%	Short Interest	18.51M	Perf Year	-25.68%
Cash/sh	5.58	P/C	0.83	EPS next 5Y	0.40%	ROE	-34.26%	52W Range	2.86 - 9.31	Perf YTD	-17.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-42.43%	ROI	-34.05%	52W High	-50.24%	Beta	1.66
Dividend TTM	-	Quick Ratio	9.84	Sales past 5Y	136.15%	Gross Margin	88.53%	52W Low	61.62%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	9.84	EPS Y/Y TTM	26.65%	Oper. Margin	-349.68%	RSI (14)	48.25	Volatility	12.00% 10.77%
Employees	274	Debt/Eq	0.14	Sales Y/Y TTM	271.44%	Profit Margin	-303.64%	Recom	1.20	Target Price	23.50
Option/Short	Yes / Yes	LT Debt/Eq	0.12	EPS Q/Q	40.38%	Payout	-	Rel Volume	0.99	Prev Close	4.32
Sales Surprise	266.09%	EPS Surprise	45.65%	Sales Q/Q	479.03%	Earnings	May 14 BMO	Avg Volume	3.01M	Price	4.63
SMA20	-6.28%	SMA50	-6.30%	SMA200	-19.09%	Trades		Volume	2,962,307	Change	7.18%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Apr-08-24	Initiated	H.C. Wainwright	Buy	$15
Apr-13-23	Initiated	Canaccord Genuity	Buy	$29
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral	$21
Dec-15-22	Initiated	Goldman	Sell	$13
Oct-06-22	Initiated	Credit Suisse	Neutral	$48
Aug-25-22	Upgrade	Stifel	Hold → Buy	$32 → $56
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$48
Feb-18-22	Initiated	RBC Capital Mkts	Outperform	$42
Sep-24-21	Initiated	Stifel	Hold	$58
Jul-12-21	Initiated	William Blair	Outperform	$92
Jul-12-21	Initiated	JP Morgan	Neutral	$50
Jul-12-21	Initiated	Jefferies	Buy	$72
Jul-12-21	Initiated	Guggenheim	Buy	$84

Show Previous Ratings

May-14-25 08:15AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:11AM	Verve Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-13-25 05:20PM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 06:05PM	Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +6.16% -5.58%
04:05PM	Loading…
May-02-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.64%
Apr-29-25 07:53AM	1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street (Motley Fool)
Apr-19-25 07:40AM	What Moved Markets This Week (Seeking Alpha)
Apr-18-25 06:36PM	Why Verve Therapeutics Zoomed 40% Higher This Week (Motley Fool)
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks) -9.26%
10:56AM	Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy' (Seeking Alpha)
Apr-15-25 12:43PM	Why Verve Therapeutics Is Skyrocketing Today (Motley Fool) +20.63%
12:27PM	VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study (Zacks)
Apr-14-25 04:12PM	Verves shares jump by more than 26% on Lilly-partnered gene therapy data (Pharmaceutical Technology) +26.38%
01:27PM	This Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life. (Barrons.com)
07:03AM	Loading…
07:03AM	Verves second swing at gene editing for heart disease shows early promise (BioPharma Dive)
07:00AM	Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 (GlobeNewswire)
Apr-11-25 07:00AM	Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 (GlobeNewswire) +6.89%
Apr-04-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.85% -7.73%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.52%
10:27AM	Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? (Insider Monkey)
07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-25-25 07:28AM	Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts (SeekingAlpha)
Mar-24-25 12:00PM	Verve gets FDA green light to expand base editing trial into US (BioPharma Dive)
07:00AM	Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose (GlobeNewswire)
Mar-03-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:25AM	Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Verve Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
06:57AM	Vertex ends gene editing research pact with Verve (BioPharma Dive)
04:05PM	Loading…
Feb-03-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.18%
Jan-29-25 07:00AM	Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire) +6.21%
Jan-23-25 09:31AM	Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last? (Zacks)
Jan-13-25 07:00AM	Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones (GlobeNewswire)
Jan-08-25 07:00AM	Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.39%
Jan-03-25 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-30-24 03:29PM	Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In? (Insider Monkey) -7.97%
Dec-29-24 06:34AM	Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Nov-29-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +27.63%
Nov-05-24 08:15AM	Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.45%
07:13AM	Verve Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-01-24 04:26PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-28-24 10:00AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
Oct-23-24 10:00AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
Oct-16-24 05:01PM	State Street Corp's Strategic Acquisition in Verve Therapeutics (GuruFocus.com)
Oct-11-24 06:15AM	Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VERV (PR Newswire)
Oct-03-24 04:56AM	Is Verve Therapeutics, Inc. (VERV) the Best NASDAQ Stock Under $5? (Insider Monkey)
Oct-02-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:15AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
Sep-20-24 04:40PM	Jim Cramer on Vertiv Holdings (VRT): I Think Its A Winner (Insider Monkey)
Sep-12-24 01:15AM	Millennium Management LLC's Strategic Acquisition in Verve Therapeutics Inc (GuruFocus.com)
Sep-08-24 04:51PM	Verve Therapeutics, Inc. (VERV): Among the Worst ARK Stocks According to Short Sellers (Insider Monkey)
11:49AM	10 Worst ARK Stocks To Buy According To Short Sellers (Insider Monkey)
Sep-05-24 08:30AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire) -9.34%
Sep-03-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.25%
Aug-08-24 10:00AM	Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV (PR Newswire)
08:40AM	Verve Therapeutics (VERV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:47AM	Verve Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-02-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.24% -5.39%
Jul-08-24 07:07PM	Why Is Verve Therapeutics, Inc. (VERV) the Most Shorted Stock Loved by Analysts Now? (Insider Monkey) +8.00% +10.76%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-01-24 04:05PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-28-24 07:00AM	Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors (GlobeNewswire)
May-31-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Verve Therapeutics Announces Leadership Update (GlobeNewswire)
May-30-24 04:01PM	Verve Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-17-24 06:27AM	Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024 (InvestorPlace) -6.27%
May-12-24 04:00PM	3 Underappreciated Stocks That Could 10x in 10 Years (InvestorPlace)
May-08-24 01:54PM	VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:10AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Verve Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 07:20AM	Verve moves forward with backup base editing therapy (BioPharma Dive)
07:00AM	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102 (GlobeNewswire)
May-03-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-19-24 10:30AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws (PR Newswire)
Apr-06-24 09:50AM	After a Serious Setback, Is Verve Therapeutics a Buy? (Motley Fool)
Apr-03-24 01:40PM	Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls (Zacks)
Apr-02-24 04:04PM	Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily) -34.95%
10:36AM	Verve Plunges To Record High After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily)
09:31AM	Verve Falls as Gene-Editing Trial Paused on Safety Issues (Bloomberg)
09:01AM	Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects (Investor's Business Daily)
07:35AM	UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics Announces Updates on its PCSK9 Program (GlobeNewswire)
03:03AM	Verve pauses base editing trial, shifts strategy after treatment side effect (BioPharma Dive)
Mar-28-24 04:51PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-24 04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-01-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-24 07:02PM	Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023 (GuruFocus.com) +21.47%
08:03AM	Verve Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-19-24 04:08PM	3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential (InvestorPlace)
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -9.23%
Feb-12-24 08:30AM	2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare (Motley Fool) +8.31%
Feb-01-24 06:30AM	Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-31-24 12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kathiresan Sekar	Chief Executive Officer	Apr 02 '25	Sale	4.15	9,822	40,761	346,686	Apr 03 05:00 PM
Nickerson Joan	Chief Administrative Officer	Apr 02 '25	Sale	4.15	2,777	11,525	17,420	Apr 03 05:00 PM
Ashe Andrew D.	See Remarks	Apr 02 '25	Sale	4.15	2,681	11,126	348,828	Apr 03 05:00 PM
Politi Jason	Chief Technical Ops. Off.	Apr 02 '25	Sale	4.15	3,235	13,425	14,226	Apr 03 05:00 PM
Dorval Allison	Chief Financial Officer	Apr 02 '25	Sale	4.15	3,350	13,903	13,280	Apr 03 05:00 PM
Lister Troy	Chief Scientific Officer	Apr 02 '25	Sale	4.15	2,189	9,084	6,952	Apr 03 05:00 PM
Dorval Allison	Chief Financial Officer	Dec 02 '24	Sale	5.64	555	3,130	5,380	Dec 03 04:30 PM
Kathiresan Sekar	Chief Executive Officer	Jun 28 '24	Option Exercise	2.87	30,000	86,100	351,128	Jul 02 07:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VERV

Verve Therapeutics Inc

Upgrade your FINVIZ experience